RoosterBio Expands Frederick, Maryland, Operations Campus
12/19/2019
The addition of 5,000 square feet to its existing 15,500 footprint supports the company’s expansion efforts and provides infrastructure to meet a growing international demand for its standardized hMSC bioprocess tools. The company is a leading supplier of human mesenchymal stem/stromal cell working cell banks and hMSC bioprocess systems.
RoosterBio reported its headquarters at The Offices at Westview serves as a center of excellence, incorporating the latest scale up bioprocessing technology and allows the company to quality test its cells and media in a variety of conditions and applications. The new space will increase shipping capabilities for a growing international network by the end of the year.
RoosterBio announced the first expansion of its facility earlier this year which served as a catalyst for its strategic international growth initiatives. The company plans to launch an international presence in Asia during the first half of 2020.
According to company officials, by strengthening its cell manufacturing solution portfolio and presence in the Asia Pacific and Europe, RoosterBio is giving more people around the world the ability to advance regenerative medicine cures.
“Our team has been working diligently this year to grow our customer base across the globe, now shipping to 26 countries and the need to expand our facility is a result of the industry validating our value proposition,” said RoosterBio’s CEO Margot Connor. “As our efforts have increased, we’ve increased our employee base by nearly 30% this year and we’re excited about our continued annual growth rate.” Connor added, “We’re taking RoosterBio to the next level in the international hMSC marketplace.”
Company officials explained, these enhancements build on RoosterBio’s proven track record of industrializing the supply chain for the new field of regenerative medicine. The products that RoosterBio has commercialized are designed to standardize hMSC manufacturing with consistent cGMP product offerings, removing years of time, and millions of dollars, from traditional mesenchymal cell therapeutic product development and clinical translation efforts. RoosterBio said it will also be launching a cGMP version of its extracellular vesicle production tools in early 2020.
Project Announcements
Climeworks Plans Calcasieu Parish, Louisiana, Direct Air CO2 Capture Operations
11/08/2024
India-Based Granules Consumer Health Expands Prince William County, Virginia, Operations
11/08/2024
Taiwan-Based Sunlit Fluo & Chemical Establishes Phoenix, Arizona, Semiconductor Material Operations
11/07/2024
Ontic Plans Miramar, Florida, MRO Operations
11/07/2024
American International Group Plans Atlanta, Georgia, Innovation Hub
11/06/2024
TMC Transformers USA Expands Waynesboro, Georgia, Manufacturing Operations
11/06/2024
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
The Role of Rail in Industrial Development
Q4 2024
-
Cold Storage: The Next Big Thing in Industrial Real Estate
Q3 2024
-
Exploring the Dynamic Landscape of Industrial Packaging Solutions
Q3 2024
-
Hydrogen Industry in Canada: A Global Leader in the Clean Energy Revolution
Q3 2024
-
Which AI Tools Work for Job Recruiters?
Q3 2024
-
Permitted Power Capacity Foreshadows Health of Regional Economies
Q3 2024